Stonnington Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Stonnington Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	$895K	Buy	9,100 +1,500	+20%	+$156K	0.23%	98
2022 Q4	$847K	Sell	7,600 -300	-4%	-$28.2K	0.23%	98
2022 Q3	$698K	Buy	7,900 +3,700	+88%	+$329K	0.2%	106
2022 Q2	$371K	Buy	4,200 +1,200	+40%	+$95.5K	0.1%	166
2022 Q1	$250K	Buy	+3,000	New	+$251K	0.06%	210
2021 Q4	–	Sell	-5,800	Closed	-$451K	–	247
2021 Q3	$451K	Buy	+5,800	New	+$458K	0.1%	175

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Stonnington Group's BMRN Position: Q1 2023 in Review

Stonnington Group increased its BioMarin Pharmaceuticals (BMRN) stake by 20% in Q1 2023, buying an estimated $156K and bringing the position to 9,100 shares worth $895K. The position accounts for 0.23% of the portfolio, ranked #98.

Stonnington Group first reported a position in BMRN in Q3 2021 and has held it in 6 quarters since. 552 funds tracked by Wall St. Rank hold BMRN as of Q1 2023.

Stonnington Group held 9,100 shares of BioMarin Pharmaceuticals worth $895K as of Q1 2023.
Stonnington Group bought 1,500 BioMarin Pharmaceuticals shares in Q1 2023, an estimated $156K.
BioMarin Pharmaceuticals made up 0.23% of Stonnington Group's portfolio in Q1 2023, its #98 holding.
Stonnington Group first reported a position in BioMarin Pharmaceuticals in Q3 2021 and has held it in 6 quarters since.
552 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2023.

Based on Stonnington Group's 13F filing for Q1 2023, filed 14 Apr 2023.